The agreement allows Circassia to use the device with many of its products including its cat and ragweed allergy therapies.

MicronJet is a microneedle-based device used to deliver vaccines and drugs directly into the skin.

The device will also induce superior immunogenicity while maintaining a lower dose than conventional doses delivered into the muscle.

Circassia vice-chairman Charles Swingland said they intend to use the device for many of their allergy programs and have received positive feedback from patients and clinicians.